This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk Poised on Strong Pipeline Amid Competition
by Zacks Equity Research
Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.
Alexion (ALXN) Gains On Positive Date From Lead Candidate
by Zacks Equity Research
Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.
ArQule (ARQL) in Focus: Stock Moves 15.6% Higher
by Zacks Equity Research
Shares of ArQule (ARQL) rose nearly 16% yesterday.
Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress
by Zacks Equity Research
Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.
Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y
by Zacks Equity Research
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2017.
Aradigm Files MAA for Bronchiectasis Candidate in the EU
by Zacks Equity Research
Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.
Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump
by Zacks Equity Research
It seems to be a wise decision for investors to drop Portola Pharmaceuticals (PTLA) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
Pfizer Gets FDA Panel Backing for New Indication for Xeljanz
by Zacks Equity Research
Pfizer's (PFE) Xeljanz received a unanimous vote from an FDA advisory committee to include the ulcerative colitis (UC) indication in its label .
Corcept Plans Korlym Label Expansion, Pipeline in Progress
by Zacks Equity Research
Corcept (CORT) is currently working on developing Korlym for additional indications. It also remains focused at the development of its pipeline progress.
Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing
by Zacks Equity Research
Bristol-Myers (BMY) Opdivo becomes the first and only FDA-approved PD-1 inhibitor for every four-week dosing.
Lilly, Boehringer to Expand Jardiance Heart Failure Program
by Zacks Equity Research
Lilly (LLY) and Boehringer plan to expand their clinical trial program for Jardiance in chronic heart failure through clinical trials.
Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink
by Zacks Equity Research
Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.
Pacira (PCRX) Posts Earnings in Q4, Revenues in Line
by Zacks Equity Research
Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.
Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress
by Zacks Equity Research
Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.
Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The top line however, drops year over year.
Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.
Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.
Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down
by Zacks Equity Research
Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.
Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
by Zacks Equity Research
Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4
by Zacks Equity Research
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View
by Zacks Equity Research
Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.